Certara, Inc.: directors' dealings · United States · SEC (Form 4)

About Certara, Inc.

Certara, Inc. is a United States-based life-sciences technology company listed on the Nasdaq market under the ticker CERT. The company focuses on biosimulation, pharmacometrics, and model-informed drug development (MIDD): specialized software and scientific services that help pharmaceutical and biotech customers predict how drug candidates behave before and during clinical development. For investors, Certara sits at the intersection of healthcare, scientific software, and regulatory data science. ([certara.com](https://www.certara.com/our-story/?utm_source=openai)) Certara’s roots go back to 2008, when Tripos International and Pharsight Corporation combined to form the company. Since then, it has expanded through a mix of organic development and targeted acquisitions, building a broader platform that now spans biosimulation, scientific informatics, and advanced chemistry tools. In 2024, Certara completed the acquisition of Chemaxon, a move designed to strengthen its scientific informatics layer and improve integration across chemistry, prediction, and biosimulation workflows. ([certara.com](https://www.certara.com/our-story/?utm_source=openai)) Operationally, Certara is organized around two core pillars. First is software, anchored by widely recognized products such as Simcyp, Phoenix, Certara D360, and Pinnacle 21. Second is services, including drug-development consulting, clinical pharmacology, modeling and simulation support, and regulatory writing. This software-plus-services model gives the company recurring revenue characteristics while also monetizing deep scientific expertise. Certara says it serves biopharmaceutical companies, academic institutions, and regulatory agencies. ([ir.certara.com](https://ir.certara.com/static-files/02bc1a09-3119-405e-80da-e9b2b1f74969?utm_source=openai)) From a competitive standpoint, Certara is positioned as a leader in biosimulation and MIDD. Its Simcyp platform is particularly important to the company’s credibility with both scientists and regulators, and Certara has long emphasized the breadth of its impact on drug-development decisions. The company’s moat is not scale alone, but a combination of domain expertise, scientific validation, and embedded workflow importance inside pharma R&D organizations. ([certara.com](https://www.certara.com/pressrelease/certaras-simcyp-consortium-celebrates-25th-anniversary/?utm_source=openai)) Certara is headquartered in Radnor, Pennsylvania, after announcing a new corporate headquarters in 2024. The company operates globally and highlights a worldwide footprint across North America, Europe, and Asia through customers, collaborations, and scientific partnerships. Recent highlights include the launch of AI-enabled QSP capabilities in 2025, fourth-quarter and full-year 2025 results reported in February 2026, and a CEO transition in 2025 with Jon Resnick appointed chief executive officer. Overall, Certara remains a specialized healthcare and pharma-tech name on Nasdaq in the United States, exposed to long-term demand for faster, more efficient, and more data-driven drug development. ([ir.certara.com](https://ir.certara.com/news-releases/news-release-details/certara-expands-biosimulation-market-ai-driven-qsp-platform/?utm_source=openai))